ResearchSafe

Stanford piece on compounded GLP-1s, doctors are worried and the FDA is finally catching up

Posted by weekendnate in Research & News - 2 points, 4 comments.

https://www.forbes.com/health/weight-loss/fda-moves-to-stop-sale-compounded-glp-1s-lmandp5

Stanford put out a solid write-up on why prescribers are nervous about compounded semaglutide and tirzepatide, and it lines up with what the FDA did in late April when it proposed pulling those peptides off the 503B bulks list. The framing is fair. They talk through the real concerns around sterility, dosing accuracy, and what happens when a shortage ends but the gray market keeps moving.

What I keep coming back to is how much of this could have been avoided with a $3 generic. Most people using compounded GLP-1s are not chasing boutique dosing or weird stacks. They just want the drug at a price they can actually afford. When the official channel costs ten times more, people find another way, and that is on the system, not the patients.

Is anyone here still sourcing compounded semaglutide after the FDA move, or did the writing on the wall push you toward branded or overseas routes?

Comments

  • nomad_brandon: Honestly the overseas route is gonna be where most people land if the FDA actually pulls the bulks list, and that is a worse outcome for safety than what we have now. You trade a compounding pharmacy that at least has some oversight for an export vendor you found on telegram, and nobody wins in that swap. The $3 generic argument is the part i keep circling back to too. If the official price was even close to reasonable, the compounding market probably shrinks on its own, and a lot of the steril
  • weekendnate: You're not wrong about the overseas swap being worse on safety, that part is obvious. The 503B pharmacies at least had USP standards and state board oversight, even if enforcement was patchy. A random export vendor has none of that, plus the shipping conditions are a black box for anything that needs cold storage. The bit I'd push back on is whether price alone fixes it. Even at $3 generic, the shortage designation goes away, so compounding shuts down legally anyway. The pricing problem and the
  • reads_labrat: Yeah the overseas jump is the part that keeps me up at night too. I track my own stuff pretty closely, and even I can tell when the community gets desperate they start making decisions they'd never make otherwise. The price lever is real, and until somebody pulls it the safety conversation is mostly theater.
  • weekendnate: Honestly "mostly theater" is the part that bothers me most. The FDA talks purity and dosing accuracy while the cash price is still $1,000 a month, so people route around them and the actual risk profile gets worse. Better compound sterility testing doesn't help if somebody is now ordering from a Telegram vendor with zero accountability. The lever that fixes the safety problem is the $3 generic, and until that exists the whole conversation is just rearranging deck chairs.

Community discussion - research and educational context only. Not medical advice.